Table 4.
Overall response rate of the azanucleoside-treated cohort of patients with higher-risk myelodysplastic syndromes (n = 632) by the risk groups within each of the five prognostic systems
| IPSS
|
IPSS-R
|
FPSS
|
MDAPSS
|
WPSS
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk group | N (%) | ORR (%) | Risk group | N (%) | ORR (%) | Risk group | N (%) | ORR (%) | Risk group | N (%) | ORR (%) | Risk group | N (%) | ORR (95% CI) |
| Low | 0 (0) | — | Very lowa | 0 (0) | — | Low | 40 (6.3) | 57.5 | Lowa | 10 (1.6) | 70.0 | Very lowa | 1 (0.1) | 0.0 |
| INT-1 | 0 (0) | — | Low | 6 (0.9) | 50.0 | INT | 490 (77.6) | 41.4 | INT-1 | 54 (8.5) | 37.0 | Lowa | 5 (0.8) | 40.0 |
| INT-2 | 440 (69.6) | 39.8 | INT | 68 (10.8) | 48.5 | High | 102 (16.1) | 39.2 | INT-2 | 184 (29.1) | 43.5 | INT | 20 (3.2) | 40.0 |
| High | 192 (30.4) | 43.1 | High | 213 (33.7) | 37.6 | High | 384 (60.8) | 41.4 | High | 323 (51.1) | 42.4 | |||
| Very high | 345 (54.6) | 43.4 | Very high | 273 (43.2) | 42.5 | |||||||||
| N/Ab | 10 (1.6) | 30.0 | ||||||||||||
| P = 0.51 | P = 0.39 | P = 0.24 | P = 0.46 | P = 0.93 | ||||||||||
Abbreviations: FPSS, French Prognostic Scoring System; IPSS, International Prognostic Scoring System; IPSS-R, revised IPSS; MDAPSS, MD Anderson Prognostic Scoring System; N/A, non-applicable; ORR, overall response rate; WPSS, World Health Organization classification-based Prognostic Scoring System. The ORR was defined as the sum of patients with complete response, partial response and hematologic improvement rates as the best achieved response. The P-values come from the χ2 test and suggests that prognostic scoring group is not associated with ORR group, for any of the prognostic scoring systems.
Not estimable owing to small cell count.
Only patients with specific WHO classifications could have a WPSS score calculated. Patients who had an ineligible WHO classification were grouped into a ‘Not Applicable’ category, so they would not be excluded from the sample.